Abiopharma

Zynex Sets Second Quarter 2025 Earnings Call

New Form 8-K - Connect Biopharma Holdings Ltd Filed: 2025-07-22 AccNo: 0001835268-25-000047 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

Healthy Extracts Expects Record Sales for Q2 2025, Driving Strong Positive Adj. EBITDA

Varex Schedules Third Quarter Fiscal Year 2025 Earnings Release and Conference Call

Viemed - Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details

Stressflation is Here: 83% of Americans Say Todays Economic Climate is Taking a Toll on Their Mental Health

Masimo - Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5

Canada Awards New Patent to bioAffinity Technologies forCyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services

New Form SCHEDULE 13D - LakeShore Biopharma Co., Ltd. Filed: 2025-07-22 AccNo: 0001213900-25-066359 Size: 229 KB

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

New Form 6-K - Sanofi Filed: 2025-07-22 AccNo: 0001193125-25-162275 Size: 54 KB

enVVeno Medical Participates in the Virtual Investor "Whats Your Story" Summer Spotlight On-Demand Conference

enVVeno Medical Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference